191 related articles for article (PubMed ID: 34910788)
21. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
[TBL] [Abstract][Full Text] [Related]
22. Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.
Andrici J; Farzin M; Clarkson A; Sioson L; Sheen A; Watson N; Toon CW; Koleth M; Stevenson W; Gill AJ
Pathology; 2016 Jun; 48(4):319-24. PubMed ID: 27114372
[TBL] [Abstract][Full Text] [Related]
23.
Xiao Y; Zhang H; Du G; Meng X; Wu T; Zhou Q; Wang Y; Tan B
Technol Cancer Res Treat; 2020; 19():1533033820970684. PubMed ID: 33176601
[TBL] [Abstract][Full Text] [Related]
24. Diversities of Calreticulin Gene Mutations in Macedonian Patients With Essential Thrombocythemia.
Panovska-Stavridis I; Eftimov A; Ivanovski M; Stojanovic A; Georgievski B; Cevreska L; Dimovski AJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):477-81. PubMed ID: 27521277
[TBL] [Abstract][Full Text] [Related]
25. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations.
Takei H; Edahiro Y; Mano S; Masubuchi N; Mizukami Y; Imai M; Morishita S; Misawa K; Ochiai T; Tsuneda S; Endo H; Nakamura S; Eto K; Ohsaka A; Araki M; Komatsu N
Br J Haematol; 2018 Jun; 181(6):791-802. PubMed ID: 29741776
[TBL] [Abstract][Full Text] [Related]
26. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Belcic Mikic T; Pajic T; Sever M
Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
[TBL] [Abstract][Full Text] [Related]
27. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.
Holmström MO; Martinenaite E; Ahmad SM; Met Ö; Friese C; Kjær L; Riley CH; Thor Straten P; Svane IM; Hasselbalch HC; Andersen MH
Leukemia; 2018 Feb; 32(2):429-437. PubMed ID: 28676668
[TBL] [Abstract][Full Text] [Related]
28. Bioinformatics analysis of prognostic significance of COL10A1 in breast cancer.
Zhang M; Chen H; Wang M; Bai F; Wu K
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32043519
[TBL] [Abstract][Full Text] [Related]
29. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
[TBL] [Abstract][Full Text] [Related]
30. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
[TBL] [Abstract][Full Text] [Related]
31. Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer.
Chen F; Fan Y; Hou J; Liu B; Zhang B; Shang Y; Chang Y; Cao P; Tan K
Aging (Albany NY); 2021 Sep; 13(17):21671-21699. PubMed ID: 34518441
[TBL] [Abstract][Full Text] [Related]
32. Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells.
Liu X; Sun N; Dong Y; Li J; Liu Y; Ren Y; Yang C; Zhang L; Zhou Y; Tong Z; Ding J; Zhao X; Liu Y; He R; Xu K; Wu Y; Huang Y; Wang H; Tao X; Liu Y
Int Immunopharmacol; 2015 Apr; 25(2):416-24. PubMed ID: 25704851
[TBL] [Abstract][Full Text] [Related]
33. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
Edahiro Y; Araki M; Komatsu N
Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
[TBL] [Abstract][Full Text] [Related]
34. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
[TBL] [Abstract][Full Text] [Related]
35. The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.
Belčič Mikič T; Pajič T; Zver S; Sever M
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806036
[No Abstract] [Full Text] [Related]
36. Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.
Pei YQ; Wu Y; Wang F; Cui W
Ann Hematol; 2016 Sep; 95(9):1391-8. PubMed ID: 27376361
[TBL] [Abstract][Full Text] [Related]
37. Calreticulin Mutations in Bulgarian MPN Patients.
Pavlov I; Hadjiev E; Alaikov T; Spassova S; Stoimenov A; Naumova E; Shivarov V; Ivanova M
Pathol Oncol Res; 2018 Jan; 24(1):171-174. PubMed ID: 28411309
[TBL] [Abstract][Full Text] [Related]
38. Possible Roles of Calreticulin in Uterine Decidualization and Receptivity in Rats and Humans.
Yoshie M; Kusama K; Tanaka R; Okubo T; Kojima J; Takaesu Y; Isaka K; Nishi H; Tamura K
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638846
[TBL] [Abstract][Full Text] [Related]
39. Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.
Holmström MO; Cordua S; Skov V; Kjær L; Pallisgaard N; Ellervik C; Hasselbalch HC; Andersen MH
Cancer Immunol Immunother; 2020 Feb; 69(2):315-324. PubMed ID: 31915854
[TBL] [Abstract][Full Text] [Related]
40. Interference of immunogenic chemotherapy by artificially controlled calreticulin secretion from tumor cells.
Zhao L; Zhang S; Chen H; Kroemer G; Kepp O; Liu P
Methods Cell Biol; 2022; 172():99-114. PubMed ID: 36064229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]